Maria Sklodowska-Curie National Research Institute of Oncology

What Maria Sklodowska-Curie National Research Institute of Oncology does

The Maria Skłodowska-Curie National Research Institute of Oncology (NIO-PIB) is Poland's largest oncology center and one of the leading oncology facilities in Central Europe. Founded in 1932 and re-designated in 2020 as a state research institute (Państwowy Instytut Badawczy) under the Polish Ministry of Health, NIO-PIB operates four sites — two in Warsaw (Roentgena and Wawelska), plus Gliwice and Kraków — delivering comprehensive oncology care, prevention, and research. The institute provides precision diagnostics (PET-CT, digital pathology), radiotherapy (linear accelerators), surgery, chemotherapy, immunotherapy, rehabilitation, psychological support, and nutritional counseling, conducting approximately 500,000 consultations per year in Warsaw alone. It coordinates the National Oncology Strategy, manages the National Cancer Registry (Krajowy Rejestr Nowotworów), operates the National Oncology Portal, and serves as Poland's reference center for rare cancers through EURACAN membership.

NIO-PIB runs over 500 simultaneous clinical trials supported by specialized infrastructure including the first-in-Poland Early Phase Research Unit, the Clinical Trial Support Center (established 2024-2026), and the Precision Oncology Excellence Center. Its technology stack includes a Biobank (established 2023) storing biological samples at -80°C and -135°C, AI-integrated radiology diagnostics via PACS-PUI integration, electronic medical documentation systems, and a Digital Medicine Center. Revenue is generated primarily through National Health Fund (NFZ) reimbursements for clinical services, supplemented by Polish state budget allocations (Ministry of Health, Ministry of Science), EU grants (EU4Health, Horizon Europe, KPO), Medical Research Agency (ABM) grants, and a Medical Fund infrastructure program (309.3M PLN, 2026-2029). The wholly-owned subsidiary OncoTransfer sp. z o.o. handles commercialization of research and technology transfer. The institute holds ESGE Training Centre certification, HR Excellence in Research recognition from the European Commission, and active memberships in OECI, ESMO, EORTC, ESTRO, ASCO, and IARC.

Name

Maria Sklodowska-Curie National Research Institute of Oncology

Legal name

Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy

Website

https://nio.gov.pl

Company type

Private

Founded year

1932

Operating status

Operating

Headcount range

11–50 employees

Short description

NIO-PIB is Poland's largest state oncology research institute, operating four sites that deliver comprehensive cancer diagnostics, treatment, and prevention while coordinating the National Oncology Strategy and National Cancer Registry. It runs 500+ clinical trials annually and treats approximately 500,000 patients per year in Warsaw.

Ownership category

akta.pro rank

Product category

Oncology Healthcare Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Specialty (except Psychiatric and Substance Abuse) Hospitals (62231), Medical Laboratories (621511), Diagnostic Imaging Centers (621512)

SIC

Services-Hospitals (8060), Services-Health Services (8000), Services-Medical Laboratories (8071)

akta.pro industry

PRIMARYHLAFAHAC

Oncology & Cancer Specialty Hospitals

Healthcare & Life Sciences/Healthcare Providers & Systems/Specialty Hospitals & Inpatient Specialty Care

SECONDARYHLAKAFAB

Medical Oncology

Healthcare & Life Sciences/Specialist Medical Practice/Hematology & Oncology

SECONDARYHLAKAFAG

Surgical Oncology

Healthcare & Life Sciences/Specialist Medical Practice/Hematology & Oncology

SECONDARYHLAKAFAF

Gynecologic Oncology

Healthcare & Life Sciences/Specialist Medical Practice/Hematology & Oncology

SECONDARYHLAKAFAM

Genitourinary Oncology

Healthcare & Life Sciences/Specialist Medical Practice/Hematology & Oncology

SECONDARYHLAFAJAK

Gynecologic Oncology & Women’s Cancer Centers

Healthcare & Life Sciences/Healthcare Providers & Systems/Women’s & Children’s Health Providers

SECONDARYHLALAGAH

Oncology Telemedicine Platforms

Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)

Keywords

• Oncology diagnostics and treatment
• Cancer clinical research
• Cancer prevention services
• National cancer registry
• Biobank and precision oncology

Headquarters

HQ city

Warsaw

HQ country

Poland

HQ region

Europe

Offices4 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain

Revenue model

1. National Health Fund (NFZ) Reimbursement: Core funding through Poland's National Health Fund for healthcare services provided to patients under public health insurance.
2. State Budget Funding: Government funding for research activities, National Cancer Registry management, and National Oncology Strategy coordination.
3. EU Project Funding: Multiple EU-funded projects including EU4Health, Horizon Europe, and national operational programs supporting infrastructure development, research, and digital transformation.
4. Patient Co-payments: Some services outside NFZ coverage available as paid services according to published fee schedule.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

The Maria Sklodowska-Curie National Research Institute of Oncology (NIO-PIB) is Poland's largest oncology center, providing comprehensive cancer diagnostics, treatment, and follow-up care across four locations (Warsaw, Gliwice, Krakow). It runs over 500 active clinical trials, a Cancer Prevention Center with free screening programs, the National Cancer Registry, a Biobank, and the National Oncology Portal. The institute also coordinates the National Oncology Strategy and serves as Poland's National Monitoring Center for cancer care.

Product overview

The Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy (NIO-PIB) is Poland's largest oncology center and a leading facility in Central Europe. The institution operates as a platform combining clinical care with research across four locations (Warsaw, Gliwice, Kraków). The core offering includes precision diagnostics and treatment services, a Cancer Prevention Center providing free screening programs (HPV testing, cytology, mammography), and over 500 active clinical trials supported by specialized units including the Early Phase Research Unit, Clinical Trial Support Center, and Precision Oncology Excellence Center. Digital infrastructure includes the National Oncology Portal, electronic medical documentation systems, a Biobank for biological sample storage, and AI-enhanced radiology diagnostics through integration with the national Platform of Intelligent Services. The institution also coordinates the National Oncology Strategy and manages the National Cancer Registry.

Differentiator

Problem solved

Functional benefit

Products and services

• Precision Diagnostics and Treatment Comprehensive cancer diagnostics and innovative treatment methods including surgery, chemotherapy, radiotherapy, immunotherapy, rehabilitation, and psychological and nutritional support for cancer patients across all cancer types.
• Cancer Prevention Center (Centrum Profilaktyki Nowotworów) Free preventive examinations including HPV HR test, liquid cytology for cervical cancer screening, and mammography for breast cancer prevention, available to the general population.
• Clinical Trials Program Over 500 active clinical trials providing cancer patients access to innovative and experimental treatment methods, including early-phase trials supported by dedicated infrastructure.
• National Cancer Registry (Krajowy Rejestr Nowotworów) National cancer registry providing comprehensive cancer epidemiology data for Poland, supporting national planning of cancer infrastructure, training, and care delivery.
• NIO-PIB Biobank Comprehensive biobanking facility collecting, processing, storing, and sharing biological materials (blood, serum, plasma, DNA, RNA, PBMC, ctDNA, tissue samples) under controlled conditions at -80°C and -135°C for scientific research and diagnostic purposes.
• National Oncology Portal (Narodowy Portal Onkologiczny) Public information portal providing cancer patients, relatives, medical staff, and the general public with information on oncology diagnostics, treatment methods, locations, effectiveness, and prevention content.
• Education and Conference Center (Centrum Edukacyjno-Konferencyjne) Modern conference and training facility hosting professional medical events, conferences, and industry gatherings with five fully equipped conference rooms including an auditorium for up to 300 attendees, available for rental.

Quantifiable outcome

• 500+ clinical trials providing patient access to innovative treatments
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability3 records

Feature4 records

Partnerships

13 partnerships are on record, tiered core.

• EURACANcoreStrategic or Co-development PartnerEuropean network for rare adult cancers. NIO-PIB serves as reference center for rare cancer treatment as EURACAN member.
• OECI (Organisation of European Cancer Institutes)coreStrategic or Co-development PartnerEuropean cancer institute network collaborating on research, best practices, and cancer care standards.
• ESMO (European Society for Medical Oncology)coreStrategic or Co-development PartnerEuropean oncology society actively participating in shaping global oncology standards.
• EORTC (European Organisation for the Research and Treatment of Cancer)coreStrategic or Co-development PartnerEuropean cancer research organization conducting clinical trials and developing treatment standards.
• ESTRO (European Society for Radiotherapy & Oncology)coreStrategic or Co-development PartnerEuropean radiotherapy society contributing to radiation oncology standards and education.
• ASCO (American Society of Clinical Oncology)coreStrategic or Co-development PartnerInternational oncology society participating in shaping worldwide oncology standards.
• IARC (International Agency for Research on Cancer)coreStrategic or Co-development PartnerWHO cancer research agency. NIO-PIB participates in WCT EVI MAP project led by IARC for WHO cancer classification.
• Polish Ministry of HealthcoreOthersGovernment ministry responsible for health policy. NIO-PIB coordinates National Oncology Strategy and serves as National Monitoring Center under ministry oversight.
• National Health Fund (NFZ)coreOthersPoland's public health insurance provider. Main funding source for healthcare services at NIO-PIB.
• ECHoS ConsortiumcoreStrategic or Co-development PartnerEuropean consortium for establishing Cancer Mission Hubs. NIO-PIB leads Task 2.2 (guidelines) and Task 5.2 (business continuity) under Prof. Iwona Ługowska.
• EUnetCCC ConsortiumcoreStrategic or Co-development PartnerEuropean network of Comprehensive Cancer Centers. NIO-PIB participates in 8 work packages across all three locations. Project value: €90M.
• IARC/WHOcoreStrategic or Co-development PartnerNIO-PIB leads package for WCT EVI MAP project (€2.7M funding) mapping evidence for WHO cancer classification, led by dr hab. Magdalena Chechlińska.
• JANE ConsortiumcoreStrategic or Co-development PartnerJoint Action on Networks of Expertise. NIO-PIB leads WP5 (poor prognosis cancers) and WP7 (post-treatment care) under Prof. Iwona Ługowska and Prof. Piotr Rutkowski.

Scale indicators6 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Memorial Sloan Kettering Cancer Center: US specialty oncology hospital and research institution. Comparable as a flagship specialty oncology institution combining inpatient care, outpatient treatment, and research.
• Karolinska Institutet: Sweden's leading medical university with major oncology research programs. Comparable as a publicly funded medical research institution with translational oncology and clinical trial activity.
• MD Anderson Cancer Center: US-based comprehensive cancer center and one of the largest specialty oncology hospitals globally. Comparable as a major tertiary oncology center combining patient care, research, and prevention programs.
• Dana-Farber Cancer Institute: Major US specialty cancer hospital and research center affiliated with Harvard. Comparable as a large-scale oncology specialty provider with deep clinical trial and translational research portfolios.
• The Institute of Cancer Research (ICR): UK research institution and degree-granting body specializing in oncology. Comparable as a publicly-oriented cancer research entity with strong clinical trial pipelines and international standing.

Direct peers

• European Institute of Oncology (IEO): Specialty oncology hospital and research center in Milan focused on cancer prevention, diagnosis, and treatment. Comparable as a specialty oncology provider with strong clinical research emphasis.
• Institut Gustave Roussy: Leading European comprehensive cancer center combining clinical care, research, and teaching. Comparable as a national-scale oncology specialty center with strong clinical trial activity, research leadership, and European network membership.
• Netherlands Cancer Institute (NKI): Specialized cancer research and treatment institute in the Netherlands. Comparable as a vertically integrated oncology hospital and research organization with strong international scientific output.
• German Cancer Research Center (DKFZ): Germany's national cancer research center with translational and clinical research programs. Comparable as a publicly funded national oncology research hub coordinating cancer strategy and clinical research.
• Istituto Nazionale dei Tumori (Milan): Italian national cancer institute providing oncology treatment, prevention, and research. Comparable as a publicly funded national specialty oncology center with research and registry functions.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks4 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/maria-sklodowska-curie-national-research-institute-of-oncology

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Maria Sklodowska-Curie National Research Institute of Oncology